Evidence map›Paper›PMID 26797453›Full record

ArticleCancer causes & control : CCC2016

Epidemiological risk factors associated with inflammatory breast cancer subtypes.

Rachel L Atkinson, Randa El-Zein, Vicente Valero, Anthony Lucci, Therese B Bevers, Tamer Fouad, Weiqin Liao, Naoto T Ueno, Wendy A Woodward, Abenaa M Brewster

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Leptin signaling in breast cancer and its crosstalk with peroxisome proliferator-activated receptors α and γ.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Tailoring Treatment for Patients with Inflammatory Breast Cancer.Current treatment options in oncology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Rachel L AtkinsonDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler St., Unit 1360, P.O. Box 301439, Houston, TX, 77230, USA.
Randa El-ZeinMD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, USA.
Vicente ValeroMD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, USA.
Anthony LucciMD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, USA.
Therese B BeversDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler St., Unit 1360, P.O. Box 301439, Houston, TX, 77230, USA.
Tamer FouadMD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, USA.
Weiqin LiaoDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler St., Unit 1360, P.O. Box 301439, Houston, TX, 77230, USA.
Naoto T UenoMD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, USA.
Wendy A WoodwardMD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, USA.
Abenaa M BrewsterDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler St., Unit 1360, P.O. Box 301439, Houston, TX, 77230, USA. abrewster@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
R25 SUPPLEMENT IN GENETIC EPIDEMIOLOGY EDUCATIONR25CA057730 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE · 1992 to 2016
$18.6M
Risk Prediction for ER Negative Breast Cancer RecurrenceR01CA172511 · NCI · BAYLOR COLLEGE OF MEDICINE · PI BONDY, MELISSA L., BREWSTER, ABENAA M · 2013 to 2017
$3.1M
(PQD4) SIGNS OF INFLAMMATORY BREAST CANCER ARE CAUSED BY STROMAL FIELD EFFECTSR01CA180061 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WOODWARD, WENDY A · 2013 to 2016
$1.9M
NCI NIH HHS 1R01CA180061-01NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA172511NCI NIH HHS R01 CA180061NCI NIH HHS R25 CA057730NCI NIH HHS R25T CA057730
6 · The paper itself

Abstract

backgroundIn this single-institution case-control study, we identified risk factors associated with inflammatory breast cancer (IBC) subtypes based on staining of estrogen receptor (ER), progesterone receptor (PR) and expression of human epidermal growth factor 2 (HER2neu) to determine distinct etiologic pathways.

methodsWe identified 224 women with IBC and 396 cancer-free women seen at the MD Anderson Cancer Center. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for associations between breast cancer risk factors and the IBC tumor subtypes: luminal (ER+ and/or PR+/HER2neu-), HER2neu+ (any ER and PR, HER2neu+), and triple-negative (ER-/PR-/HER2neu-).

resultsIn multivariable analysis, compared with women age ≥26 at first pregnancy, women age <26 had a higher risk of triple-negative IBC (OR 3.32, 95% CI 1.37-8.05). Women with a history of breast-feeding had a lower risk of triple-negative (OR 0.30; 95% CI 0.15-0.62) and luminal IBC (OR 0.35, 95% CI 0.18-0.68). A history of smoking was associated with an increased risk of luminal IBC (OR 2.37; 95% CI 1.24-4.52). Compared with normal-weight women, those who were overweight or obese (body mass index ≥25 kg/m(2)) had a higher risk of all three tumor subtypes (p < 0.01 for all subtypes).

conclusionOverweight or obese status is important modifiable risk factor for IBC of any subtype. Modifiable risk factors, age at first pregnancy (≥26), breast-feeding, and smoking may be associated with specific IBC subtypes. These results highlight the importance of evaluating epidemiologic risk factors for IBC for the identification of subtype-specific prevention strategies.

Indexed as

AdultAgedAged, 80 and overAge FactorsBody Mass IndexBreast FeedingCase-Control StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansInflammatory Breast NeoplasmsLogistic ModelsMiddle AgedObesityPregnancyReceptors, EstrogenERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneCancer epidemiologyInflammatory breast cancerLifestyle factorsObesityReproductive factors

Identifiers

PMID26797453
PMCPMC4778706
OpenAlexW2274413360

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.